By granting global partners access to real-world insights and synthetic data, the new partnership will accelerate research and inspire new therapy development to drive better patient outcomes
TORONTO, ON, July 28, 2022 (GLOBE NEWSWIRE) – MCI Onehealth Technologies Inc. (“MCI” or the “Company”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development.
“MCI’s collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs.
“Whether through MCI’s clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will quickly translate healthcare data and research into improved health and quality of life for patients,” said Dr. Alexander Dobranowski, MD, CEO of MCI.
Real-world patient health journeys that MCI’s tech-enabled network is uniquely able to capture offer a comprehensive picture to researchers who benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone technology to load, organize and protect MCI-generated patient data and use this data to find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research.
MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome common barriers that slow clinical data projects’ progress. This solution has been shown to reduce hospitalizations and prevent unnecessary morbidity and mortality in some use cases.
“We’re thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond.
“Together, we can provide tailored clinical insights that meet clients’ needs, and from those, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes,” said Josh Rubel, Chief Commercial Officer of MDClone.
In keeping with its strategy to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The ADAMS Platform’s unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data but composed entirely of artificial patients aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact.
MCI’s audience for health insights continues to grow in Canada and will further benefit from access to MDClone’s global roster of top-tier health system and pharma relationships. The collaboration with MDClone immediately gives MCI entry into the clinical insights and analytics sectors in the U.S. and Israel, including headquarter-level decision-makers of global pharma and life science leaders.
“As a commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we gain a superior — and unique — offering to acquire new partners, fueling MCI health insight services expansion into international markets,” added Dobranowski.
